Implantable Cardioverter Defibrillators Market By Type (Transvenous ICDs {Biventricular ICD, Dual-Chamber ICD, and Single-Chamber ICD} and Subcutaneous ICDs), By Application (Sudden Cardiac Arrest (SCA), Ventricular Tachycardia, Heart Failure, and Others), By End-user (Hospitals, Ambulatory Surgical Centers, Cardiac Clinics, and Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Implantable Cardioverter Defibrillators market accounted for USD 9.26 Billion in 2024 and is expected to reach USD 18.9 Billion by 2035, growing at a CAGR of around 6.7% between 2025 and 2035.  The ICD market is a worldwide business associated with designing, producing, and distributing such devices aimed at monitoring and treating abnormal heart rhythms. These ICDs are surgically implanted in patients suffering from potentially life-threatening arrhythmias, providing critical electrical shocks that help restore normal heart rhythms where necessary.

Some market drivers include the rising prevalence of cardiovascular diseases, advanced ICD technology, and increased awareness of heart disease management. Key players are medical device companies that have developed innovations like device miniaturization and wireless monitoring. The market will grow because of the aging population and improving healthcare technologies. 

Report Scope:

Market Dynamics

Rising cardiovascular disease mortality fuels demand for leadless ICDs and minimally invasive procedures

The growth in the market for ICDs is being significantly influenced by minimally invasive procedures, and more specifically, leadless ICDs. These devices offer an alternative version of traditional ICDs which are smaller and less invasive and do not require wires or leads, thereby reducing complications and improving recovery times in patients. According to the American Heart Association, CVD remains the leading cause of death in the United States and produced 928,741 deaths in the year 2020.

Since the prevalence of CVD is increasing, there is a growing need for less invasive more effective treatments. Such leadless ICDs are winning the race, especially due to reduced risk of infection, fewer hospital stays, and rapid recovery. Such patients include the elderly or those suffering from other comorbid conditions. This is likely to further lead to the increased adoption of these sophisticated devices, thereby expanding the market for ICDs and achieving better health care.

Government Healthcare Investments Boost Accessibility and Adoption of ICD Treatments

The public healthcare expenditure in North America and Europe affects the accessibility and cost of ICD treatment. Healthcare spending in the United States grew by 4.1% to $4.5 trillion in 2022, above a growth rate of 3.2% in 2021. Such massive increases in health expenditures ensure that adequate resources are available for patients seeking advanced treatment options such as ICD.

The European government continues to focus on improving access to lifesaving treatments. Investments in the health sector enable widened use of new technologies, such as leadless ICDs, and enhance treatment options for the patient. More patients accessing minimally invasive and advanced cardiac care associated with increased investments in the health sector may further increase the growth of the ICD market.

Adverse Patient Reactions to Defibrillation Shocks Limit Widespread Acceptance of ICDs

One major restraint to the universal acceptance of ICDs is adverse patient responses to electrical shocks from these devices. Most ICDs save lives, but some patients go through pain, discomfort, or anxiety as they are subjected to defibrillation shocks, and this lowers the quality of life in that person. At times, patients suffer physical injuries such as burns and muscle damage due to the shock.

Poor adherence to ICD therapy may also be provoked by psychological effects such as post-traumatic stress or fear of future shocks. These concerns may dissuade patients from opting for or continuing treatment. Potential adverse reactions underscore the need for further innovation to continue improving ICD designs and risk reduction, which could help to improve patient acceptance and hence expand the market.

Technological innovations like leadless ICDs drive market growth and patient preference

Technological innovations in leadless ICDs are likely to open up vast opportunities for market expansion and patient preference. Leadless ICDs provide a more minimally invasive approach than traditional ICDs, foregoing leads and thereby eliminating infections and device complications. Leadless ICDs have been proven, according to the FDA, to be effective in offering defibrillation therapy, but with reduced risks from traditional ICDs.

As healthcare technology investments increase, the development and adoption of advanced devices like leadless ICDs continue to gain momentum. Improved patient outcomes associated with shorter hospital stays and enhanced recovery times are contributing to the growing demand for minimally invasive treatments, thereby driving the adoption of leadless ICDs, and expanding the market further.

Customizable ICDs for Pediatric and Congenital Heart Disease Patients Create New Niche Market Opportunities

Customizable ICDs to specific groups of patients, like pediatric or congenital heart disease (CHD) patients, are particularly suitable for specific groups of patients, such as pediatric or congenital heart disease (CHD) patients. The Centers for Disease Control and Prevention (CDC) report that 1 in 100 babies is born with a congenital heart defect. As they grow older, this continuously rising number of patients needs more specific and age-binned, customized devices in cardiology care.

Furthermore, NIH shows research and funding currently being put into place to advance the treatment of those suffering from pediatric or congenital heart disease, with millions annually set aside for discovering unique, specialized medical technology.

With customized ICDs, patients of these specific populations could enjoy better patient results and outcomes due to the more precise anatomical and physiological needs of the target populations. With the number of patients needing individualized treatments growing, the market for such devices is likely to expand and there will be new niche opportunities in the ICD market.

Industry Experts Opinion

"We are deeply grateful for the trust we've received from the medical community. We develop solutions to ease physicians' workloads and improve patient care through holistic and connected approaches. Our innovations are rooted in trustworthy customer relations, feedback and our extensive expertise in cardiac device implants and leads."

• Dr. David Hayes, Chief Medical Officer, BIOTRONIK, Inc.

Segment Analysis

Based on the type, the Implantable Cardioverter Defibrillators market has been classified into Transvenous ICDs and Subcutaneous ICDs. The Transvenous ICDs segment is further classified as Biventricular ICD, Dual-Chamber ICD, and Single-Chamber ICD. Transvenous ICDs, more specifically Dual-Chamber ICD and Biventricular ICD (CRT-D), are currently leading the market because of their ability to deliver complete therapy in treating a variety of arrhythmias and heart failure.

Dual-chamber ICD allows for precise monitoring of the atrium and ventricle, thereby managing complicated heart conditions better. Biventricular ICDs combine defibrillation with CRT to enhance heart function in patients with heart failure, making them a first-line therapy for more severe cases. Such features make transvenous ICDs the most widely used in clinical practice. 

Based on the application, the Implantable Cardioverter Defibrillators market has been classified into sudden cardiac arrest (SCA), ventricular tachycardia, heart failure, and others. Sudden Cardiac Arrest (SCA) is the dominant application for ICDs it is a serious state where immediate intervention is required. ICDs are designed to detect and correct dangerous arrhythmias, like ventricular fibrillation, which usually causes SCA. If the heartbeat stops or becomes irregular, an electrical shock from the ICD will return normal rhythm to the heart, potentially saving that patient's life. 

Regional Analysis

North America is considered the largest market for ICDs, as it is the region with a well-developed healthcare infrastructure, high healthcare expenditure, and a huge demographic population with increasing old age. Under North America, the United States has led and held a larger portion of the market due to well-embedded health care, widespread application of medical technologies, and higher incidence rates of cardiovascular diseases.

According to the Centers for Disease Control and Prevention, heart disease is the cause of death in the United States, and this, therefore calls for life-saving devices such as ICDs. Reimbursement policies and government funding further spur the adoption of ICDs and make North America the leading market for ICDs.

The Asia Pacific is the most promising ICD market, mainly because of access improvements to healthcare services, increasing consciousness of cardiovascular illnesses, and increased investments in healthcare. China, India, and Japan are seeing a growing level of cardiovascular disease due to changes in lifestyle, aging populations, and urbanization.

Improvement in healthcare systems and rising medical technology investments contribute to the growing adoption of sophisticated devices such as ICDs. The region also supports the affordability and access to these devices because of government initiatives and rising income levels in Asia. This is key to underpinning growth in the global Implantable Cardioverter Defibrillators market.  

Competitive Landscape

Major players such as Medtronic, Abbott Laboratories, Boston Scientific, and Biotronik have captured the current ICD market, continuing to innovate their products and expand product offerings in an industry developing advanced cardiac care. For instance, with Medtronic receiving FDA approval on its Micra AV leadless pacemaker, the market is increasingly tending toward less-invasive products. Abbott has gained momentum with its Tango leadless ICD, and it has enhanced the comfort levels of the patient and reduced further complications.

Boston Scientific introduced its RESOLUTE coronary stent system and Emblem S-ICD, the subcutaneous ICD to reduce complications. The growth in the market is driven by continued technological advancements, strategic mergers and collaborations, and companies' focus on device performance, patient outcomes, and cost-effectiveness. The trend of focusing on personalized, minimally invasive solutions is expected to enhance the competition further in this area.

Implantable Cardioverter Defibrillators Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In May 2024, Medtronic plc, a global healthcare technology leader, announced that the company's investigational OmniaSecure™ defibrillation lead met both its primary safety and effectiveness endpoints with performance exceeding prespecified goals in the global Lead Evaluation for Defibrillation and Reliability (LEADR) Pivotal Trial.
• In January 2024, BIOTRONIK announced the milestone achievement of 100,000 single lead implantable cardioverter-defibrillators (ICDs) implanted in patients with DX Technology, which provides for direct atrial sensing for the detection and monitoring of atrial fibrillation (AF).
• In October 2023, Medtronic plc, a medical technology and services leader, announced that the U.S. Food and Drug Administration (FDA) has approved the Aurora EV-ICD™ MRI SureScan ™ and Epsila EV ™ MRI SureScan ™ defibrillation led to treat life-threatening, dangerously fast heart rhythms, including sudden cardiac arrest (SCA).

Report Coverage:

By Type

• Transvenous ICDs
  • Biventricular ICD
  • Dual-Chamber ICD
  • Single-Chamber ICD
• Subcutaneous ICDs

By Application

• Sudden Cardiac Arrest (SCA)
• Ventricular Tachycardia
• Heart Failure
• Others

By End-user

• Hospitals
• Ambulatory Surgical Centers
• Cardiac Clinics
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Medtronic
• Abbott Laboratories
• Boston Scientific Corporation
• Biotronik SE & Co. KG
• Philips Healthcare
• St. Jude Medical
• GE Healthcare
• Cochlear Limited
• Dexcom, Inc.
• Hoya Corporation
• Smith & Nephew
• LivaNova PLC
• MicroPort Scientific Corporation
• Zoll Medical Corporation
• Cardinal Health, Inc.

Frequently Asked Questions (FAQs)